peptidefix

Peptides / Retatrutide / United States

Retatrutide in the United States

Legal status, what it is, and the listed suppliers in the United States that list it.

Legal status in the United States

Not an approved medicine. Investigational. Eli Lilly plans to apply to the FDA in the first quarter of 2027 (Lilly results release, August 2026).

As understood at 2026-09-25. Verify with the FDA.

What Retatrutide is

Retatrutide is a synthetic peptide developed by Eli Lilly that acts on three hormone receptors at once: GLP-1, GIP and glucagon. It is an investigational drug in phase 3 clinical trials for obesity and type 2 diabetes and is not yet licensed anywhere. Its long duration of action comes from a fatty-acid chain attached to the peptide.

Full Retatrutide page: targets and research →

Listed suppliers in the United States

1 of the 10 suppliers we list in the United States list Retatrutide. Listed, not endorsed: each row is the supplier’s own stated terms.

American Peptides United States Products are sold for Research Use Only and not for Human Consumption. Not for human or veterinary use.

Clinical Research

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Bajaj HS, Welch M, Shah P, et al. (2026). The Lancet. human humans, n=537, phase 3 randomised double-blind placebo-controlled trial (48 sites in the USA, Mexico and India)
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial
Coskun T, Wu Q, Schloot NC, et al. (2025). The Lancet Diabetes & Endocrinology. human adults with type 2 diabetes, phase 2 substudy, n=189 enrolled (103 with paired DXA scans)
Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats
Petersen J, Merrild C, Holm SK, et al. (2026). Nature Metabolism. animal diet-induced obese male rats
661 Retatrutide monotherapy matches the effectiveness of anti-PD-1 immunotherapy in a preclinical model of pancreatic cancer
Marathe SJ, Bohm MS, Powell Z, et al. (2025). Journal for ImmunoTherapy of Cancer (SITC 2025 abstract supplement). animal diet-induced obese male C57BL/6J mice with implanted pancreatic tumour cells, n=10 per group